Publications by authors named "Puneeth Guruprasad"
Article Synopsis
- Many patients treated with FDA-approved CAR T cells see their disease progress, especially with solid cancers and certain types of blood cancers like T cell lymphomas.
- A major challenge in adoptive T cell therapies is the dysfunction of CAR T cells, which struggle to expand and last after being infused.
- The study reveals that knocking out the CD5 gene using CRISPR-Cas9 can improve the antitumor abilities of CAR T cells by enhancing their function and persistence, suggesting CD5 as a key target for improving T cell therapies.
Article Synopsis
- - The study identifies the interaction between BTLA on T cells and HVEM on regulatory T cells as a major factor limiting the effectiveness of T cell-based immunotherapies in tumors.
- - High levels of BTLA in CAR T cells are linked to poorer treatment outcomes, prompting researchers to delete BTLA to improve the T cells' tumor-fighting abilities.
- - By removing BTLA, T cells show enhanced signaling and function, suggesting that targeting the BTLA-HVEM interaction could boost the success of CAR T cell therapies.
Article Synopsis
- This study focuses on the need for efficient and cost-effective methods to measure important characteristics of CAR T cells during their manufacturing process, as the popularity of these therapies is rising.
- Researchers compared a new device called the Moxi GO II with established devices, the Multisizer Coulter Counter and BD LSRFortessa, to evaluate cell number, size, viability, and basic features of CAR T cells.
- Findings show that the Moxi GO II can accurately provide these measurements and is comparable to the gold standard instruments, making it a promising tool for monitoring CAR T-cell characteristics in both research and clinical settings.
Article Synopsis
- - Researchers hypothesized that developing a novel anti-CD19 scFv, h1218, could improve the efficacy of CAR T-cell therapies for patients with relapsed B-cell non-Hodgkin lymphoma, addressing issues linked to the commonly used FMC63 variant.
- - The new h1218-CART19 product demonstrated superior performance in preclinical studies, effectively targeting lymphoma cells that had developed resistance to FMC63 and showing enhanced anti-cancer activity due to reduced cell death and better cell expansion.
- - A phase I clinical trial was initiated to evaluate the safety and effectiveness of h1218-CART19 in patients with relapsed or refractory NHL, building on promising preclinical findings.
Article Synopsis
- Immunotherapy has changed the landscape of cancer treatment, with methods like immune checkpoint blockade and T-cell transfer showing great success in fighting various cancer types.
- A major challenge is that cancer cells often resist apoptosis (programmed cell death), making them harder to eliminate; improving their susceptibility to apoptosis is crucial for effective treatment.
- The review highlights current strategies to enhance T-cell therapies by increasing cancer cell apoptosis sensitivity while also addressing how apoptosis affects the survival of T-cells in the tumor environment.
Article Synopsis
- Chimeric antigen receptor T-cell (CART) immunotherapy shows promise for treating B-cell non-Hodgkin lymphoma (NHL), but around two-thirds of patients do not respond effectively.
- A study found that chromosomal alterations in the BCL-2 gene, which helps cancer cells resist apoptosis, are linked to decreased survival rates in patients treated with anti-CD19 CART.
- To improve efficacy, researchers created venetoclax-resistant CART cells by modifying BCL-2 and found that this approach, combined with venetoclax, enhanced anti-tumor activity, suggesting new strategies for improving CART therapy in resistant lymphoma cases.
Article Synopsis
- Immunotherapies like immune checkpoint blockade and adoptive cell transfer have greatly improved cancer treatment but understanding tumor resistance remains challenging.
- New technologies, particularly single-cell RNA sequencing, are providing detailed insights into the tumor microenvironment and immune system that traditional bulk genomics can't capture.
- This technique has identified important factors and cell types that influence tumor behavior, paving the way for the development of more effective immunotherapies in the future.
Investigating individual red blood cells (RBCs) is critical to understanding hematologic diseases, as pathology often originates at the single-cell level. Many RBC disorders manifest in altered biophysical properties, such as deformability of RBCs. Due to limitations in current biophysical assays, there exists a need for high-throughput analysis of RBC deformability with single-cell resolution.
View Article and Find Full Text PDF